Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes

被引：0
|
作者：
Dreesen, E. [1 ]
Laharie, D. [2 ]
Lambrecht, G. [3 ]
Bossuyt, P. [4 ]
Buisson, A. [5 ]
Filippi, J. [6 ]
Van Hootegem, P. [7 ]
D'Haens, G. [8 ]
Vermeire, S. [9 ,10 ]
Gils, A. [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Hosp Haut Leveque, Bordeaux, France
[3] Damiaan Hosp, Oostende, Belgium
[4] Imelda Hosp, Bonheiden, Belgium
[5] Hosp Estaing, Clermont Ferrand, France
[6] Hosp Archet, Nice, France
[7] Sint Lucas Hosp, Brugge, Belgium
[8] Acad Med Ctr, Amsterdam, Netherlands
[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P572
引用
收藏
页码：S396 / S397
页数：3
相关论文
共 50 条
  • [31] Evidence of infliximab dose stability in Crohn's disease
    Cohen, R
    Farr, C
    Ziskind, M
    Tandon, N
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) : S228 - S228
  • [32] Durability of Infliximab Dose Intensification in Crohn’s Disease
    Kirk K. Lin
    Fernando Velayos
    Elena Fisher
    Jonathan P. Terdiman
    Digestive Diseases and Sciences, 2012, 57 : 1013 - 1019
  • [33] Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
    Bultman, E.
    de Haar, C.
    van Liere-Baron, A.
    Verhoog, H.
    West, R. L.
    Kuipers, E. J.
    Zelinkova, Z.
    van der Woude, C. Janneke
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) : 335 - 341
  • [34] Population pharmacokinetics of single dose infliximab in patients with Crohn's disease.
    Fasanmade, AA
    Zhu, YW
    Wagner, C
    Pendley, C
    Davis, HM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P66 - P66
  • [35] Durability of Infliximab Dose Intensification in Crohn's Disease
    Lin, Kirk
    Terdiman, Jonathan E.
    GASTROENTEROLOGY, 2010, 138 (05) : S695 - S695
  • [36] Recommendations for Dose Adjustments of Infliximab in Crohn's Disease Patients with Higher Clearance
    Andersson, Helena
    Eser, Akexander
    Huisinga, Wilhelm
    Reinisch, Walter
    Kloft, Charlotte
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S27 - S27
  • [37] Patterns of Dose Escalation Amongst Patients with Ulcerative Colitis and Crohn's Disease Treated with Vedolizumab vs. Infliximab in the United States
    Khalid, Javaria Mona
    Raluy-Callado, Mireia
    Li, Qian
    Luo, Michelle
    Lasch, Karen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S316 - S317
  • [38] Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels
    Allegretti, Jessica R.
    Carrellas, Madeline
    Hamilton, Matthew
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2016, 150 (04) : S421 - S421
  • [39] Desensitisation to infliximab in patients with Crohn's disease
    Lelong, J
    Duburque, C
    Fournier, C
    Colombel, JF
    Desreumaux, P
    Tonnel, AB
    Wallaert, B
    REVUE DES MALADIES RESPIRATOIRES, 2005, 22 (02) : 239 - 246
  • [40] INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED
    Allegretti, Jessica R.
    McClure, Emma L.
    Marcus, Jenna
    Norton, Beth Ann
    Hamilton, Matthew
    Winter, Rachel
    De Silva, Punyanganie
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2020, 158 (06) : S461 - S461
12345